Health Condition 1: I258- Other forms of chronic ischemic heart disease
Conditions
Interventions
Intervention1: Ursodeoxycholic acid: 300 mg two tablets to be taken with meal for 3 days
Control Intervention1: Identical placebo: Identical looking placebo to be taken with meal for 3 days
Sponsors
Post Graduate Institute of Medical Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: known or suspected coronary artery disease patients
Exclusion criteria
Exclusion criteria: 1. Less than 18 years 2.Patient not willing to give the consent 3.Any patient with contraindication to use UDCA as interventional drug eg. gall stone disease, gall bladder inflammation, biliary tract occlusion, biliary colic and hypersenstivity to the drug etc. 4.Patient with hepatic disorder affecting the tracer uptake 5.Pregnant and lactating female patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) Interpretability of the MPS scan at 30 minutes and 60 minutes of the study in both the groups (case & control). (2) Percentage reduction in the liver tracer activity at 60 minutes as compared to 30 minutes in both the groups. (3) Myocardial to liver tracer activity ratio at 30 minutes & 60 minutes in both the groups.Timepoint: During MPS procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| To facilitate early imaging in patients undergoing MPSTimepoint: During MPS procedure | — |
Countries
India
Contacts
Public ContactProf B R Mittal
PGIMER
Outcome results
None listed